B cell development, activation and differentiation

Eirini Sevdali, PhD Laboratory of Rheumatology, Autoimmunity and Inflammation School of Medicine UOC

10/6/2025

5th Immunology Workshop for Clinicians

Overview

- B cell development and maturation
- B cell activation and differentiation
- B cell tolerance



B cells: past – present - future



Where do B cells develop and mature

From hematopoietic stem cells to plasma cells



Schultheiss et al, Sem Immun 2022

What makes a lymphocyte a B cell? The immunoglobulin (B cell antigen receptor)



Antibody classes and biological activities

Different isotypes and subtypes of antibodies perform different effector functions.

- Different C regions of IgH chains
- ➢ 5 classes: IgM, IgG, IgA, IgD, IgE
- Subclasses: 4 for IgG (IgG1, IgG2, IgG3, IgG4), 2 for IgA (IgA1, IgA2)
- <u>All isotypes carry either kappa or</u> lamda chains

| , T | IgG IgG C _γ IgM IgM IgM IgM IgM IgM IgM IgM IgM IgM | T . | | IgA C _a | V | | lgD | 7 | 8 | gE | 7 |
|--------|--|------|----------------|-----------------------|------|------|----------------|------|------|--------------------|----|
| | νμ · · · · · · · · · · · · · · · · · · · | | Immunoglobulin | | | | | | | | |
| | | lgG1 | lgG2 | lgG3 | lgG4 | lgM | lgA1 | lgA2 | lgD | lgE | í. |
| | Heavy chain | γ1 | γ2 | γ ₃ | γ4 | μ | α ₁ | α2 | δ | з | - |
| | Molecular weight (kDa) | 146 | 146 | 165 | 146 | 970 | 160 | 160 | 184 | 188 | |
| | Serum level (mean adult mg/ml) | 9 | 3 | 1 | 0.5 | 1.5 | 3.0 | 0.5 | 0.03 | 5×10 ⁻⁵ | |
| | Half-life in serum (days) | 21 | 20 | 7 | 21 | 10 | 6 | 6 | 3 | 2 | |
| | Classical pathway of complement activation | ++ | + | +++ | _ | ++++ | _ | - | _ | _ | |
| - | Alternative pathway of complement activation | - | - | - | _ | - | + | - | - | - | |
| | Placental transfer | +++ | + | ++ | -+ | - | - | - | - | - | |
| | Binding to macrophage and phagocyte Fc receptors | + | - | + | -+ | - | + | + | - | + | |
| | High-affinity binding to mast cells and basophils | - | - | - | - | - | - | - | - | +++ | |
| | Reactivity with staphylococcal Protein A | + | + | -+ | + | - | - | - | - | - | |

Beyond antigen binding: effector mechanisms of antibodies



How are we protected against the great variety of pathogens?

The complexity of human Ig loci

The germline organization of the heavy and light chains loci



All antibody molecules share the same basic structural characteristics recarding their constant regions but display remarkable variability in the regions that bind antigens



The V(D)J recombination

Susumu Tonegawa

Nobel Prize for Physiology or Medicine in 1987 for "his discovery of the genetic principle for generation of antibody diversity."



- The order of rearrangements is pre-defined: first the heavy chain, then the light chain
- The spontaneous addition/deletion of nucleotides before the joining of VDJ fragments increases diversity (junctional diversity)





Every B cell contains a unique rearranged DNA sequence for the heavy chain locus and a unique DNA sequence for the light chain locus

Generation of diversity in B cells

| | Immuno | globulin | |
|--|-------------|----------|----|
| Mechanism | Heavy Chain | κ | λ |
| Variable (V) segments | 45 | 35 | 30 |
| Diversity (D) segments | 23 | 0 | 0 |
| D segments read in all three reading frames | Rare | _ | |
| N region diversification | V-D, D-J | None | |
| Joining (J) segments | 6 | 5 | 4 |
| Total potential repertoire with junctional diversity | ~10'' | | _ |

Combinatorial diversity: Different combinations of gene segments united by V(D)J recombination produce different antigen receptors.

45 V_H genes x 23 D genes x 6 J genes = 6210 possible recombinations 35 V_k genes x 5 J genes = 175 possible recombinations (120 for the λ locus) 10⁶ possible antibody molecules

Junctional diversity: Removal or addition of nucleotides at the junctions of the V and D, D and J, or V and J segments at the time these segments are joined.

10¹¹ potential antibody repertoire

B cell development beyond the BM



Pieper K, Grimbacher B, Eibel H, JACI 2013

How are B cells activated and differentiated?

Antigen recognition by the B cell receptor triggers signaling pathways for B cell activation and differentiation



B cells as professional antigen presenting cells



Yuseff et al, Nat Rev Imm 2013

Recirculation of naïve B cells and their differentiation into antibody-secreting and memory B cells

Naïve follicular B cells scan follicles for antigens Recognition of antigen on follicular dendritic cells
results on B cell activation

3 pathways of differentiation:

- T cell dependent [germinal center (GC) reactions)]
- T cell independent
- Extrafollicular pathway (EF)

All pathways differ regarding their ability to generate memory B cells and plasma cells





The generation of long-term immunity: the T cell-dependent antibody responses



The primary antibody repertoire is diversified by two processes that modify the rearranged immunoglobulin gene The mechanisms of somatic hypermutation and class-switch recombination



Extrafollicular B cell activation versus follicular/germinal center reaction



| Feature | Follicular/Germinal Center | Extrafollicular | | | |
|-----------------------------------|--|---|--|--|--|
| Localization | Secondary follicles | Medullary cords of lymph nodes and at junctions between T cell zone and red pulp of spleen | | | |
| CD40 signals | Required | Required | | | |
| Specialized T cell help | T _{FH} cells in germinal center | Extrafollicular T helper cells | | | |
| AID expression | Yes | Yes | | | |
| Class switching | Yes | Yes | | | |
| Somatic hypermutation | High rate | Low rate | | | |
| Antibody affinity | High | Low | | | |
| Terminally differentiated B cells | Long-lived plasma cells and memory cells | Short-lived plasma cells (life span of ~3 days) | | | |
| Fate of plasma cells | Bone marrow or local MALT | Most die by apoptosis in secondary lymphoid tissues where they were produced | | | |
| B cell transcription factors | Bcl-6 | Blimp-1 | | | |

The effect of cytokines on dominating EF or GC responses



Elsner R and Shlomchik M, Immunity 2019

Do memory B cells exist in the absence of T cells? The T cell-independent antibody responses

- Antigen: polysaccharide and/or lipopolysaccharide structures
- Immunoglobulin: mainly IgM antibodies (low affinity) with broad reactivity/polyreactivity, IgA
- Class switching mediated by cytokines of nonlymphoid origin (BAFF, APRIL, TGF-β)
- Rapid response
- Germinal centers can be formed \rightarrow collapse earlier
- Synergistic function of TLRs
- Polysaccharide vaccines (pneumococcal vaccine) can induce quite long-lived protection



Heterogeneity in the memory B cell pool offers multilayered defense upon reinfection.

Re-activation upon antigen encountering → rapid differentiation into antibody-secreting cells and production of high-affinity antibodies

Primary and secondary humoral immune responses

"new view"

Both naïve and memory B cells contribute to the generation of a wide repertoire of antibodies that can effectively protect throughout life

Plasma cells: the mediators of long-term immunity

Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors

Xiaocong Yu¹*, Tshidi Tsibane²*, Patricia A. McGraw¹, Frances S. House¹, Christopher J. Keefer¹, Mark D. Hicar¹, Terrence M. Tumpey¹, Claudia Pappas²¹, Lucy A. Perrone^{*}, Osvaldo Martinez², James Stevens²⁴, Ian A. Wilson⁴, Patricia V. Aguilar², Eric L. Altschule², Christopher F. Basler² & James E. Crowe Jr⁴

survivors to the 1918 pandemic virus. Here we show that of the 32 individuals tested that were born in or before 1915, each showed seroreactivity with the 1918 virus, nearly 90 years after the pandemic. Seven of the eight donor samples tested had circulating B cells that secreted antibodies that bound the 1918 HA. We isolated B cells from subjects and generated five monoclonal antibodies that showed potent neutralizing activity against 1918 virus from three separate donors. These antibodies also cross-reacted with the genetically similar HA of a 1930 swine H1N1 influenza strain, but did not cross-react with HAs of more contemporary human influenza viruses. The antibody genes had an unusually high degree of somatic mutation. The antibodies bound to the 1918 HA protein with high affinity, had exceptional virus-neutralizing potency and protected mice from lethal infection. Isolation of viruses that escaped inhibition suggested that the antibodies recognize classical antigenic sites on the HA surface. Thus, these studies demonstrate that survivors of the 1918 influenza pandemic possess highly functional, virus-neutralizing antibodies to this uniquely virulent virus, and that humans can sustain circulating B memory cells to viruses for many decades after exposure-well into the tenth decade of life.

| Na | ive B cell | Plasmablast | Short-lived plasma cell | Long-lived plasma cell |
|--------------------------------------|----------------------------|--|----------------------------|---|
| | Ď | Contraction of the second seco | | |
| Blimp-1 | - | ++ | ++ | +++ |
| Lifespan | ++ | + | + | +++ |
| Proliferation | - | ++ | - | - |
| Location | BM, SLO, blood | SLO, Blood | SLO | BM, LP |
| Isotype | lgM/D | All isotypes | IgM>IgG | IgG>IgA>IgM |
| Ab secretion rate | - | ++ | ++ | ++++ |
| Glucose uptake | - | ++ | ++ | +++ |
| Autophagy | + | ++ | ++ | +++ |
| mTORC1 activity | - | + | + | +++ |
| UPR | - | +++ | *+++ | +++ |
| Tellier and Nutt I Immunol. 2019. | Eur. J. ⁴⁹ F | Respond to B co depletion and munosuppress | ell | Refractory → chronicity of autoimmune refractoriness |

How B cells survive in the absence of an antigen? The role of the BAFF/APRIL system

2 cytokines – 3 shared receptors

Vincent F et al, Nat Rev Rheum 2017

Distinct expression pattern of BAFF/APRIL receptors correlates with their function

Pieper et al, JACI 2013

Memory B cells do not depend on BAFF/APRIL for their survival → resistant to anti-BAFF treatment

How B cells do not respond to self antigens?

Eliminating self-reactive B cells: mechanisms of tolerance

More than half of the nascent B cells in initially express autoreactive antibodies

 \rightarrow most of these autoantibodies are removed from the repertoire before maturation into naïve B cells.

Sun et al. Nat Rev Neurol. 2020

T cell-dependent and T cell-independent extrafollicular activation pathways in autoimmunity

Excess of BAFF promotes the survival and selection of immature B cells from the BM to the periphery

Ectopic germinal centres sustain antigen-specific and disease-specific autoimmune responses

Salivary glands in Sjogren

Synovium in RA

Bombardieri et al, Nat Rev Reum 2017

5th Immunology Workshop for Clinicians

Targeting B cells in autoimmunity

Abeles et al, Annu. Rev. Immunol. 2024

BiTE targeting the 9G4 BCR idiotype \rightarrow precision immunotherapy for the selective depletion of autoreactive B cells in SLE

Liu et al, Arthritis Rheumatol. 2024

Decoding the BCR repertoire for dissecting the immunopathological mechanisms of B cells in autoimmune disease

Relative balance between pathologic/normal B cells determines disease course and response to treatment.

Disease prevention Treatment failure and/or and/or remission disease exacerbation Memory B cells Transitional IL-12p40 naive B cells IFN, TNF IL-10, TGF (10) naïve B cells Pathogenic B-Protective Bcell functions cell functions Pathogenic E Potective E cell functions

Manjarrez-Orduño et al. J Invest Dermatol. 2009

Identification of new therapeutic targets

Open question: Would the BCR repertoire of B cells localized in the secondary lymphoid organs or the inflamed tissues be the same with the ones in the circulation?

| 19:30-20:30 Pharma industry / Biotech perspectives in it | nmunology |
|---|---|
| Chair: | DT Boumpas |
| CART cells in autoimmune diseases | (Cristopher Sjowall, Bristol Myers Squib) |
| Novel B cell directed therapies | (Roberta Manfroni, Zenas BioPharma) |
| Immunology pipeline | (A. Moulis, Medical Director, AbbVie) |

"I have many ideas, but often they don't work. In discoveries, the most important thing is to do the experiment."

Georges J.F. Köhler

Nobel Prize in Physiology or Medicine 1984 for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies

Antigen receptors can bind antigens through their CDRs that are complementary to the size and shape of the antigen

Degn, S.E., Tolar, P. Nat Rev Immunol 2025